arrow
A

Antonio Ramos-Montoya

AstraZeneca
H指数:28
被引数:3,481

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity

蛋白质组指导的药物发现图谱并缓解治疗降解剂毒性

2026-10-090
OAAI
Discovery of AZD9750; an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer
2026-01-290
PRE
Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK
2022-07-076
OA
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

VEGF通路抑制增强PARP抑制剂在卵巢癌中的功效,而与BRCA状态无关

2021-11-0638
OAAI
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition
2021-03-3011
OA
Independence of HIF1a and androgen signaling pathways in prostate cancer

前列腺癌中HIF1a与雄激素信号通路的独立性

2020-05-2528
OAAI
The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
2019-12-1863
OAAI
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
2019-11-07237
OAAI
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry
2018-11-0229
OAAI